169 results about "Anticoagulant drug" patented technology

A microfluidic, chip-based assay device has been developed for measuring physical properties of an analyte (particularly, whole blood or whole blood derivatives). The technologies can be applied to measure clotting times of whole blood or blood derivatives, determine the effects of anticoagulant drugs on the kinetics of clotting / coagulation, as well as evaluate the effect of anticoagulant reversal agents. These technologies can additionally be used to optimize the dosage of anticoagulation drugs and / or their reversal agents. The assay is independent of the presence of anticoagulant; clotting is activated by exposure of the blood sample in the device to a glass (or other negatively charged material such as oxidized silicon) surface, which activates the intrinsic pathway and can be further hastened by the application of shear flow across the activating materials surface. The absence of chemical activating agents and highly controlled and reproducible micro-environment yields a point of care universal clotting assay.

The invention belongs to the field of analytical chemistry and particularly relates to a method of separating and testing (S)-Rivaroxaban and enantiomers thereof by liquid chromatography. The method for separating and testing (S)-Rivaroxaban and enantiomers (impurities) thereof by liquid chromatography is characterized in that a polysaccharide derivative is used as a chiral chromatographic column of filler and a mixed solution of low alcohol or low alkane or low alcohol is used as a moving phase. According to the separation and detection method provided by the invention, (S)-Rivaroxaban can be effectively separated from enantiomers thereof, wherein the separation degree reaches over 1.5 and complete baseline separation is achieved, so that the quality of (S)-Rivaroxaban can be accurately and effectively controlled. The separation method provided by the invention can be used for separating and detecting the (S)-Rivaroxaban and enantiomers thereof within 80 minutes. The method provided by the invention can be used for simply, quickly and accurately separating and detecting (S)-Rivaroxaban and optical isomers thereof.

The invention relates to a sustained-release preparation composition of an anticoagulant drug ticagrelor (also called brilinta) and a preparing method thereof. The composition comprises ticagrelor and other pharmaceutical accessories. The composition is characterized in that the composition can be quick in acting, also can ensure persistent effectivity within 24 hours, and further can reduce Cmax based on guarantee of the effective plasma concentration, thereby improving patient compliance and reducing drug safety problem in the premise without reduction of curative effect.

Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots are provided wherein fibrinolytic or anticoagulant drugs are biocompatibly coupled to red blood cell carriers.

The invention discloses an anticoagulant polypeptide, belonging to the field of biomedicine. The primary structure of the anticoagulant polypeptide is shown as the general formula: (D)-FPRP-X1-X2-X3-X4-X5-QGDFEPIPEDAYDE-NH2. The invention has the advantages that the invention designs and synthesizes one type of anticoagulant polypeptide according to the structure characteristics and action mode of thrombin and Bivalirudin which is anticoagulant drug, and the polypeptide can inhibit the activity of the thrombin efficiently and specifically; furthermore, the number of amino acid in the anticoagulant polypeptide is equal to that of the Bivalirudin, thus synthesis is easy, and the activity of anticoagulation is stronger.

The invention discloses a preparation method of long-term preservable plasma matrix universally used in quality control products. The universally used plasma matrix includes, but is not limited to, plasma which can be used for preparing blood coagulation quality control products, anticoagulant quality control products, and antithrombase quality control products. The invention also relates to a lyoprotectant and a lyophilization process of the universally used plasma. The lyoprotectant is prepared by mixing polyols, amino acids and inorganic salts according to certain proportions.

The present application generally relates to methods to prevent or treat bleeding and / or hypocoagulation in an individual in need thereof, and compositions for use in such methods. The methods comprise administration of FVa, preferably an APC resistant FVa (such as superFVa), alone or in combination with FVIIa, preferably rhFVIIa (such as NovoSeven® or another FVIIa having enhanced activity or half-life). When administered in combination, FVa and FVIIa elicit a synergistic benefit when used to treat or prevent bleeding or hypocoagulation in subjects in need thereof, e.g., subjects with a genetic disorder such as hemophilia or an acquired bleeding disorder or other condition associated with bleeding or hypocoagulation such as hemorrhagic stroke or shock, trauma, surgery or dysmenorrhea or individuals who produce inhibitory antibodies against procoagulants such as FVIII or FIX or who have been administered an overdose of an anticoagulant drug such as a direct Xa or direct thrombin inhibitor or a Novel Oral Anti-Coagulant (NOAC) or demonstrate unexplained bleeding. Also, the invention relates to the use of a superFVa alone or in combination with FVIIa or other procoagulant or prohemostatic agent to prevent, treat or reverse APC-associated bleeding, e.g., as the result of APC overproduction (such as through serious injury and / or hemorrhagic shock) or APC or other anticoagulant therapy, e.g., in the treatment of inflammatory disorders or sepsis disease.

The invention discloses a multidirectional valve hydrocephalus shunt valve with antibacterial and anticoagulant functions, and preparation and an application method thereof, and belongs to the field of medical equipment. Two ends of a drainage tube are sealed through a silicone hose; a plurality of long seams are axially cut on the side wall at one end of the drainage tube, so as to form a valve type channel; and a hole is punched in the side wall at the other end of the drainage tube, which is served as a channel for allowing intracranial liquid to flow into the hydrocephalus shunt. At least one type of antibacterial drug permeates in the shunt valve body, so as to prevent wound from being infected; and meanwhile, anticoagulant drugs are connected with the surface of the tube wall in a surface grafting manner, so as to prevent blood corpuscle and protein in hydrocephalus from being adhered to the inner tube wall and causing lumen blockage. The shunt valve is used for the drainage of hydrocephalus from brain to other body cavities, the antibacterial and anticoagulant design can effectively prevent infection and vessel clogging in hydrocephalus shunt, the multidirectional valve design at the remote end can prevent liquid from flowing back, and the hydrocephalus shunt valve is multifunctional.

A kit for warfarin personalized medication related gene SNP locus detection and a PCR amplification method using same. The kit includes two forward primers and one reverse primer for detecting gene VKORC1 (-1639G / A) SNP locus and / or two forward primers and one reverse primer for detecting gene CYP2C9 (1075A / C) SNP locus. The kit provided by the invention can realize VKORC1 (-1639G / A) and CYP2C9 (1075A / C) SNP locus detection with high efficiency and high throughput, so as to achieve warfarin dose quantification control, and even play a certain role for prevention of thrombotic disease, selection of anticoagulant drug, research and development of the novel anticoagulant drug, and prognosis of thrombotic disease.

The invention relates to a preparation method of total saponins of panax stipuleanatus and application of an anticoagulant drug, and belongs to the technical field of biological medicine. The preparation method comprises the steps that panax stipuleanatus powder is added into an extraction solvent, microwave extraction is carried out for 20-40 minutes at 60-100 DEG C, filtration is carried out toobtain residues and an extracting solution, then the residues are extracted 2-3 times in the same extraction condition, the extracting solutions are mixed, then decompression concentration is carriedout to obtain an extract, saturated n-butanol is used for extracting the extract to obtain a n-butanol extract, the n-butanol extract is separated by adopting MCI column chromatography, an ethanol / water solvent system is used for elution to obtain ethanol eluent, and the ethanol eluent is concentrated and dried to obtain the total saponins of the panax stipuleanatus. The total saponins of the panax stipuleanatus can be used for preparing a drug composition for treating thrombotic diseases and / or resisting blood coagulation.

Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots, which are capable of selective dissolution of pathological nascent clots formed intravascularly, with minimal risk of unwanted dissolution of pre-existing hemostatic clots, are provided wherein fibrinolytic or anticoagulant drugs are biocompatibly coupled to red blood cell carriers.

The invention relates to a novel technology for preparing disaccharide fragment of an anticoagulant drug fondaparinux sodium intermediate. The technology has the advantages of short reaction route, high efficiency, and easy purifying of the intermediate, and is suitable for commercial production of the full protection heparin pentasaccharide.